Fig. 5

Lung cancer PDO-based high-throughput screening (HTS) and cancer organoid-based diagnosis reactivity prediction (CODRP) index analysis to crizotinib. DRC-based drug response analysis using ALK-positive (A) and ALK-negative (B) patient-derived organoids to crizotinib. (C) Comparative analysis of drug response based on the AUC and CODRP indices for crizotinib; The CODRP index is calculated as a Z-score value based on different mean and standard deviation (SD) values of crizotinib for individual PDO, considering the AUC index, cancer stage, and PDO growth rate through multiple linear regression (Mean, SD, and sample number of Crizotinib: 0.71, 0.26, 17). In the conventional AUC index-based analysis for the crizotinib, the sensitivity was 40% and the specificity was 58.3%, but as a result of the CODRP index-based drug sensitivity analysis, the analysis performance improved to 100% sensitivity and 66.6% specificity